Publications

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

Journal for ImmunoTherapy of Cancer / Sep 22, 2022

Poster Presentation With Sanofi presenting Pre-Clinical Translational Data of SAR444881 (BND-22)

ASCO 2022 Annual Meeting

BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models

Poster Presentations at AACR 2020 Virtual Annual Meeting